STAAR Surgical to Report Fourth Quarter and Fiscal Year Results on February 23, 2022

Rhea-AI Summary

STAAR Surgical Company (NASDAQ: STAA) will release its financial results for the fourth quarter and fiscal year ending December 31, 2021, on February 23, 2022, post-market. A conference call is scheduled for the same day at 4:30 p.m. ET to discuss these results and operational progress. Participants can join via phone or webcast from the investor relations section on their website. As a leader in ophthalmic surgery for over 30 years, STAAR specializes in implantable lenses designed to enhance visual freedom, with over 1 million Visian ICLs implanted worldwide.

Positive

• Scheduled conference call indicates transparency and engagement with investors.
• Over 1 million Visian ICLs implanted showcases strong market acceptance of products.

Negative

• None.

LAKE FOREST, Calif.--(BUSINESS WIRE)-- STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today announced that it will release financial results for the fourth quarter and fiscal year ended December 31, 2021 on Wednesday, February 23, 2022 after the market close.

STAAR will host a conference call and webcast on Wednesday, February 23 at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and operational progress. To access the conference call (Access Code 142350), please dial 844-200-6205 for domestic participants and 929-526-1599 for international participants. The live webcast can be accessed from the investor relations section of the STAAR website at www.staar.com.

A taped replay of the conference call (Replay Code 610748) will be available beginning approximately one hour after the call’s conclusion for seven days. This replay can be accessed by dialing 866-813-9403 for domestic callers and 929-458-6194 for international callers. An archived webcast will also be available at www.staar.com.

About STAAR Surgical

STAAR, which has been dedicated solely to ophthalmic surgery for over 30 years, designs, develops, manufactures and markets implantable lenses for the eye with companion delivery systems. These lenses are intended to provide visual freedom for patients, lessening or eliminating the reliance on glasses or contact lenses. All of these lenses are foldable, which permits the surgeon to insert them through a small incision. STAAR’s lens used in refractive surgery is called an Implantable Collamer® Lens or “ICL,” which includes the EVO Visian ICL™ product line. More than 1,000,000 Visian® ICLs have been implanted to date and STAAR markets these lenses in over 75 countries. To learn more about the ICL go to: www.discovericl.com. Headquartered in Lake Forest, CA, the company operates manufacturing and packaging facilities in Aliso Viejo, CA, Monrovia, CA and Nidau, Switzerland. For more information, please visit the Company’s website at www.staar.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20220209005281/en/

Investors & Media

Brian Moore

Vice President, Investor, Media Relations and Corporate Development

(626) 303-7902, Ext. 3023

bmoore@staar.com

Source: STAAR Surgical Company

FAQ

When will STAAR Surgical release its financial results for Q4 2021?

STAAR Surgical will release its financial results on February 23, 2022.

What time is the STAAR Surgical conference call on February 23, 2022?

The conference call will take place at 4:30 p.m. ET.

How many Visian ICLs has STAAR Surgical implanted?

STAAR Surgical has implanted over 1 million Visian ICLs globally.

Where can I find the webcast for STAAR Surgical's conference call?

The webcast can be accessed from the investor relations section on STAAR's website.

What does STAAR Surgical focus on in its business?

STAAR Surgical specializes in developing and marketing implantable lenses for ophthalmic surgery.